Developer docs
API playgroundTry for free, no card

Search company profiles

SAB Biotherapeutics

Full company profile

uuid0000ebt

Namestring
SAB Biotherapeutics
Legal namestring
SAB Biotherapeutics, Inc.
Websiteurl
sab.bio
Company typeenum
Public
Founded yearint
2014
Descriptiontext

SAB Biotherapeutics (NASDAQ: SABS), commonly branded SAB BIO, is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Miami Beach, Florida, with a research and development campus in Sioux Falls, South Dakota. The company is built around a single proprietary technology platform — Tc-Bovine transchromosomic cattle — which is genetically engineered to produce fully human, multi-specific polyclonal immunoglobulin G (hIgG) antibodies without requiring human donors or convalescent plasma. Across seven clinical trials dosing 700 individuals, SAB BIO reports zero cases of serum sickness and zero neutralizing anti-drug antibodies, supporting a differentiated safety and redosing profile relative to existing rabbit-derived anti-thymocyte globulin comparators.

The company's lead clinical asset is SAB-142, a multi-specific, fully human anti-thymocyte globulin (hATG) being developed as a disease-modifying immunotherapy for newly diagnosed Stage 3 Type 1 Diabetes (T1D) patients aged 5–40, with the goal of preserving pancreatic beta cell function and C-peptide production rather than managing insulin symptoms. SAB-142 is currently in the registrational Phase 2b SAFEGUARD trial across approximately 65 global sites, with topline data expected in the second half of 2027. Beyond SAB-142, the Tc-Bovine platform underpins a broader pipeline of hIgG candidates for additional immune and autoimmune disorders, and clinical data has been presented at ADA, FOCIS, ISPAD, and the Immunology of Diabetes Society Congress.

SAB Biotherapeutics is publicly traded, has 51–100 employees, and operates a pre-commercial, partnership- and capital-driven business model with no marketed products and no recurring product revenue. The company has funded operations primarily through equity financings — including a $130M preferred-stock placement led by RA Capital Management (Oct 2023), a $175M private placement led by Sanofi and Blackstone (Jul 2025), and an $85M underwritten public offering (Mar 2026) — alongside historical U.S. Department of Defense COVID-19 contract closeout payments. Manufacturing is outsourced to Emergent BioSolutions Canada under a five-year exclusive agreement, and SAB relies on investor conferences, scientific congresses, and sell-side analyst coverage to support future commercial launch of SAB-142.

Short descriptiontext

SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing SAB-142, a fully human multi-specific anti-thymocyte globulin for newly diagnosed Stage 3 Type 1 Diabetes, produced via its proprietary Tc-Bovine transchromosomic cattle platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMiami, United States
HQ citystring
Miami
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical drug development, polyclonal antibody therapeutics, type 1 diabetes treatment, transchromosomic antibody platform, autoimmune disease immunotherapy
Industry3 codes
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGADAA
Bioanalytical Testing (PK/ADA/NAb)
NAICS code4 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
Product category
Type 1 Diabetes Biotherapeutics
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Future product sales of SAB-142
TypeOne Time License
Description

Clinical-stage biopharmaceutical company with no marketed products; future recurring/one-time revenue expected from commercial launch of SAB-142 (and follow-on pipeline candidates) for Stage 3 Type 1 Diabetes and other autoimmune indications. Estimated adjusted peak U.S. revenue potential of approximately $2.2 billion (with 45% probability of success) per Jefferies initiation.

sab.bio
2Government and defense contract funding
TypeManaged Services
Description

Historical government contract revenue from the U.S. Department of Defense for COVID-19 prototype research (final closeout settlement of $16.8 million, with an $8.2 million tranche received in January 2023).

biospace.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Pricing details1 tier
1Not publicly disclosed — clinical-stage company with no commercial product pricing.
ModelOther
Notes

Pricing not publicly disclosed.

sab.bio
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing SAB-142, a multi-specific, fully human anti-thymocyte globulin (hATG) disease-modifying immunotherapy for Stage 3 Type 1 Diabetes (T1D). SAB-142 is produced using the company's proprietary Tc-Bovine transchromosomic cattle platform, which generates fully human, multi-specific polyclonal immunoglobulin G (hIgG) antibodies without requiring human donors or convalescent plasma. The lead asset is currently being evaluated in the registrational Phase 2b SAFEGUARD trial in newly diagnosed adult, adolescent, and pediatric T1D patients aged 5-40, with topline data expected in 2H 2027.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 700 individuals dosed across 7 clinical trials with zero serum sickness and zero neutralizing anti-drug antibodies
+3 more records
Product overview1 text field

SAB Biotherapeutics (SAB BIO) is a clinical-stage biopharmaceutical company that operates a single integrated platform-plus-lead-asset architecture: its proprietary Tc-Bovine transchromosomic cattle platform produces fully human, multi-specific polyclonal antibodies (hIgG), and that platform's lead output is the drug candidate SAB-142, a fully human anti-thymocyte globulin (hATG) currently in a registrational Phase 2b SAFEGUARD trial for Stage 3 type 1 diabetes. The Tc-Bovine platform underpins all of SAB BIO's hIgG therapeutic candidates, while SAB-142 represents the most advanced clinical program derived from that platform.

Product and service1 record
1SAB-142
CategoryLead drug candidate (clinical-stage biopharmaceutical)
Description

SAB-142 is a multi-specific, fully human anti-thymocyte globulin (hATG) disease-modifying immunotherapy being developed to delay the onset and progression of Stage 3 Type 1 Diabetes (T1D). It modulates multiple immune cells involved in destroying pancreatic beta cells, with the goal of preserving C-peptide and enabling life-long redosing with a superior safety profile (no serum sickness, low/no immunogenicity). It is being evaluated in the registrational Phase 2b SAFEGUARD trial in newly diagnosed adult, adolescent, and pediatric T1D patients aged 5-40.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-04-28
Description

Five-year Master Manufacturing Services Agreement signed April 28, 2026, under which Emergent BioSolutions Canada will perform clinical and commercial manufacturing of SAB-142 at its Winnipeg, Manitoba facility. Emergent holds sole and exclusive manufacturing rights during the term, with SAB reserving rights to contract an alternative source in limited circumstances. The deal is valued at approximately $50 million, with $36 million contingent on future regulatory approval and downstream milestones; represents a minimum aggregate spend commitment over five years from FDA approval.

2Clinical Advisory Board (Cardiff University, University of Florida, UCSF, University of Melbourne, KU Leuven, University of Miami, Royal Melbourne Hospital)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Advisory partnership with leading T1D key opinion leaders across major academic institutions including Colin Mark Dayan (Cardiff), Michael Haller (U Florida), Stephen Gitelman (UCSF), Thomas Kay (U Melbourne), Chantal Mathieu (KU Leuven), Jay S. Skyler (U Miami), and John Wentworth (Royal Melbourne Hospital). The Clinical Advisory Board guides SAB BIO on SAB-142 clinical development.

sab.bio
Strategic tierCoreTypeOthersAnnounced on2023-01-18
Description

Government partner on a COVID-19 prototype research contract that delivered a final closeout settlement of $16.8 million, including an additional $8.2 million tranche received in January 2023. The relationship supported SAB BIO's development of anti-COVID-19 hIgG therapeutics.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Acquired by Sanofi in 2023 for its lead asset teplizumab (Tzield), a disease-modifying anti-CD3 therapy approved for Stage 2 Type 1 Diabetes. Direct therapeutic competitor to SAB-142 in the disease-modifying T1D space and validates the strategic value SAB BIO is pitching to Sanofi as an investor.

TypeBroad incumbent
Description

Late-stage developer of VX-880/zimislecel, a stem cell-derived islet cell therapy for Type 1 Diabetes. Competes for the same newly diagnosed T1D patient population with a different disease-modifying mechanism (cell replacement vs. immune modulation).

3ViaCyte
TypeDirect peer
Description

Clinical-stage developer of stem cell-derived beta cell replacement therapies (e.g., VC-02, partnered with CRISPR Therapeutics) for Type 1 Diabetes. Targets the same newly diagnosed T1D population with a complementary cell-based rather than antibody-based mechanism.

4Dompé Farmaceutici
TypeEmerging player
Description

Italian biopharma developing ladarixin, an oral IL-8 inhibitor in clinical trials for new-onset Type 1 Diabetes. Emerging disease-modifying T1D player with similar Phase 2/3 trial positioning but a small-molecule rather than polyclonal antibody approach.

TypeBroad incumbent
Description

Global biopharma with approved Tzield (teplizumab) for Stage 2 T1D and strategic investor in SAB BIO's July 2025 $175M placement. The most important incumbent in disease-modifying T1D and a likely acquirer or commercial partner if SAB-142 succeeds.

6Sigilon Therapeutics (acquired by Eli Lilly)
TypeEmerging player
Description

Developed encapsulated cell therapies for Type 1 Diabetes (SIG-002) using Afibromer technology; acquired by Eli Lilly in 2023. Competes in the same T1D disease-modifying space via cell encapsulation rather than antibody-mediated immune modulation.

TypeEmerging player
Description

Clinical-stage developer of dasiglucagon (ready-to-use glucagon) for T1D hypoglycemia rescue and broader metabolic disease pipeline. Overlaps with SAB BIO in the T1D therapeutics market with an adjacent (hypoglycemia) rather than disease-modifying focus.

TypeBroad incumbent
Description

Major diabetes incumbent with broad insulin franchise (Humalog, Lyumjev) and acquired Sigilon Therapeutics for T1D cell therapy development. Overlaps in T1D therapeutics broadly and represents a potential strategic acquirer of SAB BIO given the SIG-002 platform bet.

TypeBroad incumbent
Description

Global diabetes leader with the broadest insulin portfolio (NovoLog, Levemir, Tresiba, Fiasp) and ongoing T1D R&D. Operates in the same patient population SAB-142 targets but with symptom-management rather than disease-modifying therapies.

TypeOthers
Description

Global plasma-derived immunoglobulin leader (Gamunex, Flebogamma) and SAB BIO's most direct infrastructure counterpart given SAB's reliance on Emergent BioSolutions (a competing plasma/biologics CDMO) for manufacturing. Comparable as a plasma-derived immunoglobulin platform incumbent though focused on replacement IgG therapy rather than polyclonal immune modulation.

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SAB Biotherapeutics

Type 1 Diabetes Biotherapeuticssab.bio

SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing SAB-142, a fully human multi-specific anti-thymocyte globulin for newly diagnosed Stage 3 Type 1 Diabetes, produced via its proprietary Tc-Bovine transchromosomic cattle platform.

What SAB Biotherapeutics does

SAB Biotherapeutics (NASDAQ: SABS), commonly branded SAB BIO, is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Miami Beach, Florida, with a research and development campus in Sioux Falls, South Dakota. The company is built around a single proprietary technology platform — Tc-Bovine transchromosomic cattle — which is genetically engineered to produce fully human, multi-specific polyclonal immunoglobulin G (hIgG) antibodies without requiring human donors or convalescent plasma. Across seven clinical trials dosing 700 individuals, SAB BIO reports zero cases of serum sickness and zero neutralizing anti-drug antibodies, supporting a differentiated safety and redosing profile relative to existing rabbit-derived anti-thymocyte globulin comparators.

The company's lead clinical asset is SAB-142, a multi-specific, fully human anti-thymocyte globulin (hATG) being developed as a disease-modifying immunotherapy for newly diagnosed Stage 3 Type 1 Diabetes (T1D) patients aged 5–40, with the goal of preserving pancreatic beta cell function and C-peptide production rather than managing insulin symptoms. SAB-142 is currently in the registrational Phase 2b SAFEGUARD trial across approximately 65 global sites, with topline data expected in the second half of 2027. Beyond SAB-142, the Tc-Bovine platform underpins a broader pipeline of hIgG candidates for additional immune and autoimmune disorders, and clinical data has been presented at ADA, FOCIS, ISPAD, and the Immunology of Diabetes Society Congress.

SAB Biotherapeutics is publicly traded, has 51–100 employees, and operates a pre-commercial, partnership- and capital-driven business model with no marketed products and no recurring product revenue. The company has funded operations primarily through equity financings — including a $130M preferred-stock placement led by RA Capital Management (Oct 2023), a $175M private placement led by Sanofi and Blackstone (Jul 2025), and an $85M underwritten public offering (Mar 2026) — alongside historical U.S. Department of Defense COVID-19 contract closeout payments. Manufacturing is outsourced to Emergent BioSolutions Canada under a five-year exclusive agreement, and SAB relies on investor conferences, scientific congresses, and sell-side analyst coverage to support future commercial launch of SAB-142.

SAB Biotherapeutics firmographics

Firmographics
Name
SAB Biotherapeutics
Legal name
SAB Biotherapeutics, Inc.
Website
https://sab.bio
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing SAB-142, a fully human multi-specific anti-thymocyte globulin for newly diagnosed Stage 3 Type 1 Diabetes, produced via its proprietary Tc-Bovine transchromosomic cattle platform.
Ownership category
akta.pro rank

SAB Biotherapeutics industry classification

Industry
Product category
Type 1 Diabetes Biotherapeutics
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGADAA
Bioanalytical Testing (PK/ADA/NAb)

Keywords

  • Biopharmaceutical drug development
  • Polyclonal antibody therapeutics
  • Type 1 diabetes treatment
  • Transchromosomic antibody platform
  • Autoimmune disease immunotherapy

Where SAB Biotherapeutics is headquartered

Location

Headquarters

HQ city
Miami
HQ country
United States
HQ region
North America

Offices4 records

Markets served

SAB Biotherapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Future product sales of SAB-142: Clinical-stage biopharmaceutical company with no marketed products; future recurring/one-time revenue expected from commercial launch of SAB-142 (and follow-on pipeline candidates) for Stage 3 Type 1 Diabetes and other autoimmune indications. Estimated adjusted peak U.S. revenue potential of approximately $2.2 billion (with 45% probability of success) per Jefferies initiation.
  2. Government and defense contract funding: Historical government contract revenue from the U.S. Department of Defense for COVID-19 prototype research (final closeout settlement of $16.8 million, with an $8.2 million tranche received in January 2023).

Pricing tiers

ModelBillingPrice
Other—Not publicly disclosed — clinical-stage company with no commercial product pricing.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels6 records

SAB Biotherapeutics product offering

Product offering

Core offering

SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing SAB-142, a multi-specific, fully human anti-thymocyte globulin (hATG) disease-modifying immunotherapy for Stage 3 Type 1 Diabetes (T1D). SAB-142 is produced using the company's proprietary Tc-Bovine transchromosomic cattle platform, which generates fully human, multi-specific polyclonal immunoglobulin G (hIgG) antibodies without requiring human donors or convalescent plasma. The lead asset is currently being evaluated in the registrational Phase 2b SAFEGUARD trial in newly diagnosed adult, adolescent, and pediatric T1D patients aged 5-40, with topline data expected in 2H 2027.

Product overview

SAB Biotherapeutics (SAB BIO) is a clinical-stage biopharmaceutical company that operates a single integrated platform-plus-lead-asset architecture: its proprietary Tc-Bovine transchromosomic cattle platform produces fully human, multi-specific polyclonal antibodies (hIgG), and that platform's lead output is the drug candidate SAB-142, a fully human anti-thymocyte globulin (hATG) currently in a registrational Phase 2b SAFEGUARD trial for Stage 3 type 1 diabetes. The Tc-Bovine platform underpins all of SAB BIO's hIgG therapeutic candidates, while SAB-142 represents the most advanced clinical program derived from that platform.

Differentiator

Problem solved

Functional benefit

Products and services

  • SAB-142 SAB-142 is a multi-specific, fully human anti-thymocyte globulin (hATG) disease-modifying immunotherapy being developed to delay the onset and progression of Stage 3 Type 1 Diabetes (T1D). It modulates multiple immune cells involved in destroying pancreatic beta cells, with the goal of preserving C-peptide and enabling life-long redosing with a superior safety profile (no serum sickness, low/no immunogenicity). It is being evaluated in the registrational Phase 2b SAFEGUARD trial in newly diagnosed adult, adolescent, and pediatric T1D patients aged 5-40.

Quantifiable outcome

  • 700 individuals dosed across 7 clinical trials with zero serum sickness and zero neutralizing anti-drug antibodies
  • +3 more outcomes

Companies that use SAB Biotherapeutics

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles3 records

SAB Biotherapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

SAB Biotherapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship and core.

  • Emergent BioSolutions Canada Inc.flagshipStrategic or Co-development Partner · 28 April 2026Five-year Master Manufacturing Services Agreement signed April 28, 2026, under which Emergent BioSolutions Canada will perform clinical and commercial manufacturing of SAB-142 at its Winnipeg, Manitoba facility. Emergent holds sole and exclusive manufacturing rights during the term, with SAB reserving rights to contract an alternative source in limited circumstances. The deal is valued at approximately $50 million, with $36 million contingent on future regulatory approval and downstream milestones; represents a minimum aggregate spend commitment over five years from FDA approval.
  • Clinical Advisory Board (Cardiff University, University of Florida, UCSF, University of Melbourne, KU Leuven, University of Miami, Royal Melbourne Hospital)coreStrategic or Co-development Partner · 1 January 2026Advisory partnership with leading T1D key opinion leaders across major academic institutions including Colin Mark Dayan (Cardiff), Michael Haller (U Florida), Stephen Gitelman (UCSF), Thomas Kay (U Melbourne), Chantal Mathieu (KU Leuven), Jay S. Skyler (U Miami), and John Wentworth (Royal Melbourne Hospital). The Clinical Advisory Board guides SAB BIO on SAB-142 clinical development.
  • U.S. Department of DefensecoreOthers · 18 January 2023Government partner on a COVID-19 prototype research contract that delivered a final closeout settlement of $16.8 million, including an additional $8.2 million tranche received in January 2023. The relationship supported SAB BIO's development of anti-COVID-19 hIgG therapeutics.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

SAB Biotherapeutics competitors and assessment

Company assessment

Direct peers

  • Provention Bio (acquired by Sanofi): Acquired by Sanofi in 2023 for its lead asset teplizumab (Tzield), a disease-modifying anti-CD3 therapy approved for Stage 2 Type 1 Diabetes. Direct therapeutic competitor to SAB-142 in the disease-modifying T1D space and validates the strategic value SAB BIO is pitching to Sanofi as an investor.
  • ViaCyte: Clinical-stage developer of stem cell-derived beta cell replacement therapies (e.g., VC-02, partnered with CRISPR Therapeutics) for Type 1 Diabetes. Targets the same newly diagnosed T1D population with a complementary cell-based rather than antibody-based mechanism.

Broad incumbents

  • Vertex Pharmaceuticals: Late-stage developer of VX-880/zimislecel, a stem cell-derived islet cell therapy for Type 1 Diabetes. Competes for the same newly diagnosed T1D patient population with a different disease-modifying mechanism (cell replacement vs. immune modulation).
  • Sanofi: Global biopharma with approved Tzield (teplizumab) for Stage 2 T1D and strategic investor in SAB BIO's July 2025 $175M placement. The most important incumbent in disease-modifying T1D and a likely acquirer or commercial partner if SAB-142 succeeds.
  • Eli Lilly: Major diabetes incumbent with broad insulin franchise (Humalog, Lyumjev) and acquired Sigilon Therapeutics for T1D cell therapy development. Overlaps in T1D therapeutics broadly and represents a potential strategic acquirer of SAB BIO given the SIG-002 platform bet.
  • Novo Nordisk: Global diabetes leader with the broadest insulin portfolio (NovoLog, Levemir, Tresiba, Fiasp) and ongoing T1D R&D. Operates in the same patient population SAB-142 targets but with symptom-management rather than disease-modifying therapies.

Emerging players

  • Dompé Farmaceutici: Italian biopharma developing ladarixin, an oral IL-8 inhibitor in clinical trials for new-onset Type 1 Diabetes. Emerging disease-modifying T1D player with similar Phase 2/3 trial positioning but a small-molecule rather than polyclonal antibody approach.
  • Sigilon Therapeutics (acquired by Eli Lilly): Developed encapsulated cell therapies for Type 1 Diabetes (SIG-002) using Afibromer technology; acquired by Eli Lilly in 2023. Competes in the same T1D disease-modifying space via cell encapsulation rather than antibody-mediated immune modulation.
  • Zealand Pharma: Clinical-stage developer of dasiglucagon (ready-to-use glucagon) for T1D hypoglycemia rescue and broader metabolic disease pipeline. Overlaps with SAB BIO in the T1D therapeutics market with an adjacent (hypoglycemia) rather than disease-modifying focus.

Others

  • Grifols: Global plasma-derived immunoglobulin leader (Gamunex, Flebogamma) and SAB BIO's most direct infrastructure counterpart given SAB's reliance on Emergent BioSolutions (a competing plasma/biologics CDMO) for manufacturing. Comparable as a plasma-derived immunoglobulin platform incumbent though focused on replacement IgG therapy rather than polyclonal immune modulation.

Market position

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

SAB Biotherapeutics social profiles

Digital presence

SAB Biotherapeutics compliance and trust

Trust signal

Compliance1 record

SAB Biotherapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SAB Biotherapeutics leadership team

Management profile

Number of profiles

Profiles8 records

SAB Biotherapeutics funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SAB Biotherapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SAB Biotherapeutics

What does SAB Biotherapeutics do?

SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing SAB-142, a multi-specific, fully human anti-thymocyte globulin (hATG) disease-modifying immunotherapy for Stage 3 Type 1 Diabetes (T1D). SAB-142 is produced using the company's proprietary Tc-Bovine transchromosomic cattle platform, which generates fully human, multi-specific polyclonal immunoglobulin G (hIgG) antibodies without requiring human donors or convalescent plasma. The lead asset is currently being evaluated in the registrational Phase 2b SAFEGUARD trial in newly diagnosed adult, adolescent, and pediatric T1D patients aged 5-40, with topline data expected in 2H 2027.

Is SAB Biotherapeutics a public or private company?

SAB Biotherapeutics is a public company. It is classified as public and is currently operating.

When was SAB Biotherapeutics founded?

SAB Biotherapeutics was founded in 2014. It employs 51 to 100 people.

Where is SAB Biotherapeutics based?

SAB Biotherapeutics is headquartered in Miami, United States, in the North America region.

How does SAB Biotherapeutics make money?

Two revenue lines are on record. Future product sales of SAB-142 is the primary driver. The others are government and defense contract funding.

Who are SAB Biotherapeutics's main competitors?

Direct peers on record are Provention Bio (acquired by Sanofi) and ViaCyte. Broad incumbents are Vertex Pharmaceuticals, Sanofi, Eli Lilly and Novo Nordisk. Emerging players are Dompé Farmaceutici, Sigilon Therapeutics (acquired by Eli Lilly) and Zealand Pharma. Grifols is listed as an others.

Does SAB Biotherapeutics have an API?

No public API is recorded for SAB Biotherapeutics.

What industry is SAB Biotherapeutics in?

SAB Biotherapeutics's product category is Type 1 Diabetes Biotherapeutics. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaSAB Biotherapeutics, Inc. (SABS) Presents at UBS Global Biopharma Conference 2026 TranscriptSAB Biotherapeutics CEO Sam Reich introduced the company's human antithymocyte immunoglobulin drug for newly diagnosed type 1 diabetes, which aims to preserve endogenous insulin production. The drug is in a pivotal Phase IIb trial, with its mechanism validated by rabbit anti-thymoglobulin data.Investing.comSAB Biotherapeutics at UBS conference: late-stage diabetes betSAB Biotherapeutics presented SAB-142, a human anti-thymocyte immunoglobulin for newly diagnosed type 1 diabetes, at the UBS Global Biopharma Conference. The drug is in a pivotal phase IIb/III trial with top-line data expected in the second half of 2027, and the company has about $200 million in cash. Pricing has not been set.Business & FinancialSAB BIO To Participate In Upcoming Investor ConferencesSAB BIO will participate in four upcoming investor conferences in November and December 2026, with CEO Samuel J. Reich presenting fireside chats and management available for one-on-one meetings. The company's lead candidate SAB-142 targets autoimmune T1D and is in Phase 2b and Phase 3 trials.NasdaqSAB Biotherapeutics (SABS) Q3 2026 Earnings Call TranscriptSAB Biotherapeutics reported a Q3 2026 net loss of $22.3 million, down from a $45.4 million net income in 2025, with $205 million in cash and a runway to 2028. The company completed SAFEGUARD enrollment and received FDA Fast Track designation for SAB-142, with topline data expected in 2027.Seeking AlphaSAB Biotherapeutics, Inc. (SABS) Q3 2026 Earnings Call TranscriptSAB Biotherapeutics held its Q3 2026 earnings call on November 5, 2026, with CEO Samuel Reich and CFO Lucy To presenting results. The company highlighted its focus on diabetes medicines during Diabetes Awareness Month. No specific financial figures or guidance were disclosed in the provided transcript.YahooSAB Biotherapeutics Inc (SABS) (Q3 2026) Earnings Call Highlights: FDA Fast-Track Win, Full ...SAB Biotherapeutics received FDA Fast-Track designation for SAB-142 in new-onset Stage 3 Type 1 diabetes, with Safeguard study enrollment complete and PRIZE study starting. The company reported a Q3 2026 net loss of $22.3 million, down from $45.4 million in Q3 2025, and holds $205 million in cash. PRIZE data is expected after Safeguard results.MarketBeatSAB Biotherapeutics (SABS) Expected to Release Quarterly Earnings on ThursdaySAB Biotherapeutics is expected to release Q3 2026 earnings on Thursday, November 5th, with analysts projecting a loss of $0.27 per share and revenue of $0.12 million. The company's stock opened at $3.35, and analysts have an average rating of Moderate Buy with a consensus target price of $12.00.American Banking and Market NewsSAB Biotherapeutics (SABS) Expected to Post Earnings on ThursdaySAB Biotherapeutics will release Q3 2026 earnings on Thursday, November 5th, with analysts expecting a loss of $0.27 per share and revenue of $0.12 million. The stock opened at $3.35, and analysts have an average rating of Moderate Buy with a target price of $12.00.MarketBeatSAB Biotherapeutics, Inc. (SABS) - What Are Investment Firms Saying About This Stock?SAB Biotherapeutics has an average analyst rating of Moderate Buy, with nine buy ratings, one hold, and one sell. The average 12-month price target is $12.00, and the stock opened at $2.84. Institutional investors hold 7.82% of the stock, with several firms increasing positions.American Banking and Market NewsSAB Biotherapeutics, Inc. (SABS) – What Are Investment Firms Saying About This Stock?SAB Biotherapeutics shares have a consensus 'Moderate Buy' rating from eleven brokerages, with an average price target of $12.00. The company reported a loss of $0.28 per share for the quarter, matching analyst estimates, and institutional investors have increased stakes, including Bank of America's 424.8% position boost.